$206.02-0.28% today
AI Take · AlgoThesis
AbbVie's P/E of 86.5 is striking—nearly triple the typical pharma peer average of 25-30—despite the stock trading 8% below its 52-week high. The elevated multiple suggests either exceptional growth expectations or a valuation that's gotten ahead of fundamentals. With RSI at 48.9, the stock shows no momentum extremes despite this premium pricing, and short interest remains negligible at just 1.37%, indicating minimal squeeze potential. The setup implies the market has priced in significant future earnings accretion, likely tied to pipeline assets or M&A expectations, leaving little room for disappointment.
Snapshot
Market cap
$367.8B
P/E
86.5
Forward P/E
13.9
EPS (TTM)
$2.38
Dividend yield
3.27%
Net margin
6.9%
ROE
95.6%
RSI (14)
49
Beta
0.29
Short % of float
1.4%
Days to cover
3.1
52w high
No
Recent headlines
Peers in Pharmaceutical Preparations
Build a thesis around ABBV
Type a thesis in plain English. AlgoThesis researches it with real data, cites sources, and hands back a tradeable basket.
Open in AlgoThesis →